文献速递骨显像与常规 SPECT肿瘤 PET/CT

PSMA-RADS 2.0与BUMP评分在[18F]PSMA-1007 PET/CT前列腺癌局灶骨摄取中的比较:多中心评估

Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer - a multicentre evaluation.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-09-01

该多中心回顾性研究纳入130例患者412个骨病灶,比较BUMP评分与PSMA-RADS v2.0对[18F]PSMA-1007 PET/CT上局灶骨摄取的鉴别能力。BUMP的AUROC为0.812,但PSMA-RADS v2.0敏感性和特异性更高(98%和96% vs 74%和80%)。在PSMA-RADS 3分不确定病灶中BUMP区分能力有限(AUROC 0.61),提示专家判读的重要性。

要点

  • BUMP评分对骨转移有良好预测能力(AUROC 0.812),但低于人工PSMA-RADS判读。
  • PSMA-RADS v2.0敏感性和特异性分别为98%和96%,优于BUMP的74%和80%。
  • 在PSMA-RADS 3分不确定病灶中,BUMP区分能力有限(AUROC 0.61)。

核心结论

  • BUMP评分对骨转移分类有良好预测能力,但表现不及人工PSMA-RADS评估。
  • 对于不确定病灶,BUMP附加价值有限,凸显专家判读的重要性。

研究设计与样本

  • 多中心回顾性分析,纳入三个三级癌症中心的[18F]PSMA-1007 PET/CT扫描。
  • 共130例患者(中位年龄70岁)的412个骨病灶,其中60.9%(n=251)为转移性。
  • 记录病灶SUVmax、CT平均Hounsfield单位和雄激素剥夺治疗状态以计算BUMP评分,并由经验丰富的放射科医生分配PSMA-RADS评分。
  • 以随访影像、PSA动力学和多学科共识确定地面真相,采用ROC分析评估诊断性能。

主要发现

  • 恶性病灶中位SUVmax高于良性病灶:7.54(IQR 10.3)对3.53(IQR 1.51)。
  • BUMP的AUROC为0.812(95% CI: 0.636-0.931),最佳阈值0.134,F1分数0.800。
  • PSMA-RADS v2.0敏感性和特异性分别为98%和96%,BUMP分别为74%和80%。
  • 在PSMA-RADS 3分不确定病灶(n=44)中,BUMP的AUROC为0.61(95% CI 0.457-0.781)。

关键数值与推荐

  • BUMP评分由SUVmax、CT平均Hounsfield单位和雄激素剥夺治疗状态构成。
  • BUMP最佳阈值为0.134,对应F1分数0.800。
  • PSMA-RADS v2.0敏感性98%、特异性96%;BUMP敏感性74%、特异性80%。

临床怎么用

  • 在[18F]PSMA-1007 PET/CT中,局灶骨摄取应优先采用PSMA-RADS v2.0进行专家判读。
  • BUMP评分可作为辅助预测工具,但在PSMA-RADS 3分不确定病灶中附加价值有限。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • BUMP在不确定病灶中区分能力有限,结论需在更广泛人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA) PET/CT is widely used in prostate cancer management, but unspecific bone uptake (UBU) remains a diagnostic challenge particularly with [18F]PSMA-1007. Bone uptake metastatic probability (BUMP) score - a composite imaging-clinical model, was compared with PSMA Reporting and Data System (PSMA-RADS, Version 2) for predicting skeletal metastases in UBU. METHODS: A real-world cohort of [18F]PSMA-1007 PET/CT scans performed at three tertiary cancer centres was retrospectively analysed. Bone lesions with focal PSMA uptake were evaluated. SUVmax, CT-derived mean Hounsfield unit and androgen deprivation therapy status were recorded to calculate BUMP score for each lesion. Lesional PSMA-RADS scores were assigned by experienced radiologists. Ground truth was established using follow-up imaging, prostate-specific antigen (PSA) kinetics and multidisciplinary consensus. Receiver operating characteristic (ROC) analyses assessed diagnostic performance. RESULTS: 130 patients (median age 70 years) with 412 bone lesions were analysed; 60.9% (n = 251) of lesions were metastatic. Median SUVmax was higher in malignant than benign lesions: 7.54 (Interquartile range (IQR) 10.3) versus 3.53 (IQR 1.51). BUMP achieved an AUROC of 0.812 (95% CI: 0.636-0.931), the optimal threshold was 0.134 yielding an F1 score of 0.800. PSMA-RADS v2.0 outperformed BUMP with higher sensitivity and specificity (98% and 96%, versus 74% and 80%). In equivocal PSMA-RADS Score 3 lesions (n = 44), BUMP showed reduced discrimination (AUROC 0.61, 95% CI 0.457-0.781). CONCLUSION: BUMP had good predictive ability for classifying bone metastases but underperformed compared with human-led PSMA-RADS assessment. For equivocal lesions BUMP offered limited added value, highlighting the importance of expert interpretation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cairns J, Arain S, Challapalli A, et al. Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer - a multicentre evaluation. Eur J Nucl Med Mol Imaging. 2026. PMID: 42678521. doi:10.1007/s00259-026-08154-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。